1. Home
  2. CHSCN vs CGEN Comparison

CHSCN vs CGEN Comparison

Compare CHSCN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHSCN
  • CGEN
  • Stock Information
  • Founded
  • CHSCN N/A
  • CGEN 1993
  • Country
  • CHSCN United States
  • CGEN Israel
  • Employees
  • CHSCN N/A
  • CGEN N/A
  • Industry
  • CHSCN Farming/Seeds/Milling
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CHSCN Industrials
  • CGEN Health Care
  • Exchange
  • CHSCN Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • CHSCN N/A
  • CGEN 117.8M
  • IPO Year
  • CHSCN N/A
  • CGEN 2000
  • Fundamental
  • Price
  • CHSCN $25.44
  • CGEN $1.47
  • Analyst Decision
  • CHSCN
  • CGEN Strong Buy
  • Analyst Count
  • CHSCN 0
  • CGEN 1
  • Target Price
  • CHSCN N/A
  • CGEN $4.00
  • AVG Volume (30 Days)
  • CHSCN N/A
  • CGEN 216.5K
  • Earning Date
  • CHSCN N/A
  • CGEN 05-19-2025
  • Dividend Yield
  • CHSCN N/A
  • CGEN N/A
  • EPS Growth
  • CHSCN N/A
  • CGEN N/A
  • EPS
  • CHSCN N/A
  • CGEN N/A
  • Revenue
  • CHSCN N/A
  • CGEN $27,589,000.00
  • Revenue This Year
  • CHSCN N/A
  • CGEN $11.81
  • Revenue Next Year
  • CHSCN N/A
  • CGEN $28.37
  • P/E Ratio
  • CHSCN N/A
  • CGEN N/A
  • Revenue Growth
  • CHSCN N/A
  • CGEN N/A
  • 52 Week Low
  • CHSCN N/A
  • CGEN $1.13
  • 52 Week High
  • CHSCN N/A
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • CHSCN 55.06
  • CGEN 53.98
  • Support Level
  • CHSCN $25.25
  • CGEN $1.38
  • Resistance Level
  • CHSCN $25.45
  • CGEN $1.56
  • Average True Range (ATR)
  • CHSCN 0.18
  • CGEN 0.08
  • MACD
  • CHSCN -0.01
  • CGEN 0.02
  • Stochastic Oscillator
  • CHSCN 61.54
  • CGEN 68.97

About CHSCN CHS Inc Preferred Class B Series 2 Reset Rate

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: